Zobrazeno 1 - 10
of 302
pro vyhledávání: '"Vanessa, Roldán"'
Autor:
Eva Soler-Espejo, Beatriz Ángela Zazo-Luengo, José Miguel Rivera-Caravaca, Raquel López-Gávez, María Asunción Esteve-Pastor, Gregory Y.H. Lip, Francisco Marín, Vanessa Roldán
Publikováno v:
The Journal of Nutrition, Health and Aging, Vol 29, Iss 1, Pp 100430- (2025)
Background: Atrial fibrillation (AF) patients often present with a higher prevalence of comorbidities, frailty, and malnutrition. We investigated if multimorbidity, frailty and malnutrition were associated with clinical outcomes in patients with AF s
Externí odkaz:
https://doaj.org/article/595bd8b2c4bd478e91424e8dea07f46e
Autor:
Romero, Vanessa Roldán
Publikováno v:
Journal of Posthuman Studies, 2020 Aug 01. 4(1), 96-106.
Externí odkaz:
https://www.jstor.org/stable/10.5325/jpoststud.4.1.0096
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Externí odkaz:
https://doaj.org/article/517c034eafba40e4888938fef2e1d9a0
Autor:
Raquel López-Gálvez, María Eugenia de la Morena-Barrio, Alberto López-Lera, Monika Pathak, Antonia Miñano, Mercedes Serrano, Delphine Borgel, Vanessa Roldán, Vicente Vicente, Jonas Emsley, Javier Corral
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-10 (2020)
Abstract Background Congenital disorders of glycosylation (CDG) are rare diseases with impaired glycosylation and multiorgan disfunction, including hemostatic and inflammatory disorders. Factor XII (FXII), the first element of the contact phase, has
Externí odkaz:
https://doaj.org/article/4bb121c4421d4dd596db13a4bed5ae77
Autor:
Ana Sánchez-Fuentes, José Miguel Rivera-Caravaca, Raquel López-Gálvez, Francisco Marín, Vanessa Roldán
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2022)
Non-vitamin K antagonist oral anticoagulants (NOACs) are a therapeutic option to prevent stroke in patients with atrial fibrillation (AF). In fact, NOACs have become the recommended choice by international clinical practice guidelines over vitamin K
Externí odkaz:
https://doaj.org/article/d59b5eb3f5154ea7aace032a335af7e8
Autor:
María Eugenia de laMorena‐Barrio, María Sabater, Belén de laMorena‐Barrio, Renee L. Ruhaak, Antonia Miñano, José Padilla, Mara Toderici, Vanessa Roldán, Juan R. Gimeno, Vicente Vicente, Javier Corral
Publikováno v:
Molecular Genetics & Genomic Medicine, Vol 8, Iss 8, Pp n/a-n/a (2020)
Abstract Background Congenital disorder of glycosylation (CDG) type I is a group of rare disorders caused by recessive mutations in up to 25 genes that impair the N‐glycan precursor formation and its transfer to proteins resulting in hypoglycosylat
Externí odkaz:
https://doaj.org/article/08b7aebd3a134b4985f9255090063400
Autor:
Francisco Marin, Marcelo Sanmartín Fernández, Iñaki Lekuona, Fernando Arribas, Gonzalo Barón-Esquivias, Vivencio Barrios, Juan Cosin-Sales, Román Freixa-Pamias, Jaime Masjuan, Alejandro I Pérez-Cabeza, Vanessa Roldán Schilling, José Manuel Vázquez Rodríguez, Carles Rafols Priu, Manuel Anguita Sánchez
Publikováno v:
Journal of Comparative Effectiveness Research. 11:1173-1184
Objective: To analyze the effectiveness and safety of rivaroxaban in patients with atrial fibrillation (AF). Methods: The clinical profile and outcomes of the EMIR study were indirectly compared with those of ROCKET-AF, eight other Spanish observatio
Autor:
María A Esteve-Pastor, José M Rivera-Caravaca, Vanessa Roldán, Marcelo Sanmartin Fernández, Fernando Arribas, Jaime Masjuan, Vivencio Barrios, Juan Cosin-Sales, Román Freixa-Pamias, Esther Recalde, Alejandro I Pérez-Cabeza, José Manuel Vázquez Rodríguez, Carles Ràfols Priu, Manuel Anguita Sánchez, Gregory Y H Lip, Francisco Marin
Publikováno v:
Esteve-Pastor, M A, Rivera-Caravaca, J M, Roldán, V, Fernández, M S, Arribas, F, Masjuan, J, Barrios, V, Cosin-Sales, J, Freixa-Pamias, R, Recalde, E, Pérez-Cabeza, A I, Rodríguez, J M V, Priu, C R, Sánchez, M A, Lip, G Y H & Marin, F 2023, ' Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban : Observations from the prospective EMIR Registry ', European heart journal. Cardiovascular pharmacotherapy, vol. 9, no. 1, pp. 38-46 . https://doi.org/10.1093/ehjcvp/pvac060
Background Assessing bleeding risk during the decision-making process of starting oral anticoagulation (OAC) therapy in atrial fibrillation (AF) patients is essential. Several bleeding risk scores have been proposed for vitamin K antagonist users but
Autor:
Olga, Gavín, Vanessa, Roldán, Pilar, Llamas-Sillero, Amparo, Santamaría, Daniel, Arumí, Susana Fernández de, Cabo
Publikováno v:
Medicina Clínica (English Edition). 159:366-371
In Spain, vitamin K antagonists (VKA) remain the standard treatment for the prevention of thromboembolic and hemorrhagic complications in patients with atrial fibrillation (AF), despite the high risks of suffering adverse effects. The objective of th
Autor:
Darío Mandaglio-Collados, Raquel López-Gálvez, Antonio José Ruiz-Alcaraz, Cecilia López-García, Vanessa Roldán, Gregory Y.H. Lip, Francisco Marín, José Miguel Rivera-Caravaca
Publikováno v:
Mandaglio-Collados, D, López-Gálvez, R, Ruiz-Alcaraz, A J, López-García, C, Roldán, V, Lip, G Y H, Marín, F & Rivera-Caravaca, J M 2023, ' Impact of particulate matter on the incidence of atrial fibrillation and the risk of adverse clinical outcomes : A review ', Science of the Total Environment, vol. 880, 163352 . https://doi.org/10.1016/j.scitotenv.2023.163352
Background: Atrial fibrillation (AF) is common and increases the risk of stroke and mortality. Previous studies have suggested that air pollution is an important risk factor for new-onset AF. Herein, we review the evidence regarding: 1) the associati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed5805362ba821bebe7ae0db42dd1131
https://vbn.aau.dk/da/publications/d3f6c52f-2f86-4c72-a86c-105807830fab
https://vbn.aau.dk/da/publications/d3f6c52f-2f86-4c72-a86c-105807830fab